Abstract
Whole Exome Sequencing (WES) studies provide important insights into the genetic architecture of serious mental illness (SMI). Genes that are central to the shared biology of SMIs may be identified by WES in families with multiple affected individuals with diverse SMI (F-SMI). We performed WES in 220 individuals from 75 F-SMI families and 60 unrelated controls. Within pedigree prioritization employed criteria of rarity, functional consequence, and sharing by ≥3 affected members. Across the sample, gene and gene-set-wide case-control association analysis was performed with Sequence Kernel Association Test, accounting for kinship.
In 14/16 families with ≥3 affected individuals, we identified a total of 79 rare predicted deleterious variants in 79 unique genes shared by ≥3 members with SMI and absent in 60 unrelated controls. Twenty (25%) genes were implicated in monogenic neurodevelopmental syndromes in OMIM, a fraction that is a significant overrepresentation (Fisher’s Exact test OR = 2.47, p = 0.001). In gene-set wise SKAT, statistically significant association was noted for genes related to synaptic function (SKAT-p = 0.014). In this WES study in F-SMI, we identify private, rare, protein altering variants in genes previously implicated in Mendelian neuropsychiatric syndromes; suggesting pleiotropic influences in neurodevelopment between complex and Mendelian syndromes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is funded by the Accelerator program for discovery in brain disorders using stem cells (ADBS) (jointly funded by the Department of Biotechnology, Government of India, and the Pratiksha trust; Grant BT/ PR17316/MED/31/326/2015
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, INDIA gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* The members of ADBS consortium are listed in the acknowledgements section
Data analysis has been updated with sections to demonstrate the effect of familial sharing and SMI on variant burden. Sample has been reduced from 310 to 280 omitting families with Alzheimer's disease from the analysis. Acknowledgement section is updated with funding information for authors.
Data Availability
All data analysis in the present work are contained in the manuscript or uploaded as supplementary files. Raw data are available upon reasonable request to the authors